Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 200 results found. Search for [ covaxin efficacy ]

Results 1 to 21 of 200
Vivek Dubey
May 6, 2021
\"The cost of the Sputnik Light vaccine globally will be less than $10 [around Rs 730], while it has simple storage requirements, at 2-8 degrees Celsius, which provide for easy logistics\"


BusinessToday.In
April 28, 2021
\"Initial positive neutralisation studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections,\" says Anurag Agrawal, Director, Institute of Genomics and Integrative Biology


PTI
April 28, 2021
Developed by Bharat Biotech in partnership with National Institute of Virology and the Indian Council of Medical Research, Covaxin was approved for emergency use on January 3


BusinessToday.In
April 25, 2021
The Hyderabad-based vaccine manufacturer has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf life


BusinessToday.In
April 24, 2021
At these rates, Covaxin will be twice as costly as Covishield, which will be sold to state governments at Rs 400 per dose and to private hospitals at Rs 600 per dose in Phase 3 of vacccination drive


BusinessToday.In
New Delhi, April 22, 2021
Adar Poonawalla, CEO, Serum Institute of India, explains the impact of the Covishield vaccine on the double mutant strain present in India. In an exclusive conversation with India Today, Poonawalla said that the COVID vaccines were initially developed with an idea to reduce the death numbers, keep people away from getting hospitalised and lower the burden on doctors. He added that Covishield has displayed 90% efficacy against all coronavirus variants, keeping people away from the need for oxygen and ventilators. On the other hand, the healthcare sector is going through an acute shortage of beds, ventilators and oxygen in India. Watch the video for more details. Also Read: COVID-19: Pfizer to supply coronavirus vaccine at 'not-for-profit' rate to Centre


PB Jayakumar
April 22, 2021
Mumbai headquartered pharma and nutraceutical specialty ingredient maker VAV Lifesciences and its subsidiary VAV Lipids is going to supply highly purified 'synthetic phospholipids' required for vaccine manufacturing in US


BusinessToday.In
New Delhi, April 22, 2021
Bharat Biotech's COVID-19 vaccine has shown an overall interim clinical efficacy of 78 per cent and 100 per cent efficacy against severe COVID-19 disease; Putting tremendous pressure on the nation's medical infrastructure, the latest surge in COVID-19 cases has driven up the demand for medical oxygen, a critical commodity in treating the respiratory ailment; At the current pace of vaccination against coronavirus, India would need another 8 years and 9 months to inoculate 70 per cent of its entire population, a threshold required to achieve herd immunity. Watch this and more news on News Blast. Read | COVID-19: Tips from psychologists to cope in these uncertain timesAlso Read | AUMs of Indian Mutual Fund industry decreases 0.5% m-o-m


Rashi Bisaria
New Delhi, April 22, 2021
New COVID-19 mutant in Bengal, escapes antibodies' immunity Scientists have found a new lineage of the SARS-CoV-2 virus named 'B.1.618' in India, which is predominantly circulating in West Bengal. This is the second lineage to be identified from the country. The infection through this variant makes plasma therapy as redundant as an investigational treatment. 600% jump in oxygen demand from hospitals Putting tremendous pressure on the nation's medical infrastructure, the latest surge in ...


BusinessToday.In
April 21, 2021
The new variant, B.1.618 is also called a major immune escape variant, as it can escape immunity even if a person has contracted the virus before and can produce antibodies against it


Joe C Mathew
April 21, 2021
\"Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use,\" said Dr Krishna Ella, MD & Chairman, Bharat Biotech


BusinessToday.In
April 21, 2021
The ICMR has said that the vaccine developed by Bharat Biotech is effective against the UK and Brazil variants of SARS-CoV-2 and the double mutant strain of the virus


BusinessToday.In
April 16, 2021
The report, titled \"Managing India's second COVID-19 wave: Urgent steps\", underlines the key elements of the second COVID-19 wave. It also suggests measures that should be taken now to help mitigate the spread of infection


BusinessToday.In
April 14, 2021
Coronavirus vaccination: After taking the first shot, the vaccine beneficiary will receive a message on his/her registered mobile number about the link to download the vaccination certificate


BusinessToday.In
April 13, 2021
Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev added that Sputnik V's production at a larger scale will start by July 2021 with plans to produce 500 million doses


BusinessToday.In
April 13, 2021
India is the leading production hub for Sputnik V. RDIF has signed pacts with Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce over 850 million doses per year


BusinessToday.In
April 12, 2021
Developed by Russia's Gamaleya national center of epidemiology and microbiology, Sputnik V is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin


BusinessToday.In
April 12, 2021
Of around 20 coronavirus vaccines in several clinical and pre-clinical stages, Russia's Sputnik V may get SEC's nod first


BusinessToday.In
April 11, 2021
Russian Direct Investment Fund (RDIF) has tied up with a host of Indian pharma companies such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the production of Sputnik V


BusinessToday.In
April 9, 2021
The move by the national committee on adverse effects following immunisation (AEFI) has come after the European's regulator said it found rare cases of blood clots among some adult recipients who were given AstraZeneca-Oxford university's vaccine shots


PAGES 1 OF 10  12345